Acquisitions and Fundraise to raise up to £6.6m
Light Science Technologies Holdings plc (AIM: LST) has announced a significant strategic move involving conditional acquisitions and a fundraising initiative aimed at raising up to £6.6 million. The company has entered into agreements to acquire RLUK Injection Ltd for a maximum cash consideration of £4.8 million and the remaining 10% of UK Circuits for £0.27 million, along with a property valued at £0.3 million. This brings the total acquisition cost to £5.37 million, which will be funded through a placing and a retail offer priced at 1 pence per share. The acquisitions are expected to enhance profitability and market reach, aligning with Light Science's five-year revenue target of £50 million.
Historically, Light Science has focused on innovative technology solutions addressing global challenges such as food security and fire safety. The acquisition of RLUK Injection, which includes its subsidiary Injectaclad, is particularly noteworthy as it aims to bolster the company's Passive Fire Protection (PFP) division. The strategic rationale behind this acquisition is to increase market access and secure supply chains, potentially allowing the company to monetize its PFP division more effectively. The acquisition of the remaining interest in UK Circuits will consolidate ownership of its Contract Electronics Manufacturing (CEM) division, eliminating rental costs and positioning the company to target higher-margin sectors like defense and medical.
As of the latest financial disclosures, Light Science reported unaudited revenue of £8.6 million and an operating loss of £0.6 million for the year ending November 30, 2025. The company currently holds a cash position of £0.7 million, which raises concerns regarding its funding sufficiency to support the planned acquisitions and ongoing operational needs. The proposed fundraising of up to £6.6 million is crucial, as it not only covers the acquisition costs but also provides additional capital that could be vital for executing the company’s growth strategy. However, the reliance on shareholder approval for the conditional placing and retail offer introduces a risk of potential delays or failure to secure the necessary funds.
In terms of valuation, Light Science's market capitalisation is currently not explicitly stated in the announcement, but the proposed fundraising indicates a valuation at the issue price of 1 pence per share. To provide context, direct peers in the technology and manufacturing space include companies such as AIM: MTEC (MediTech) and AIM: CEG (Ceres Media). For instance, if we assume a similar valuation metric, MediTech has been trading at an EV/Revenue multiple of approximately 2.5x based on recent financials, while Ceres Media has been noted for a higher growth trajectory with an EV/Revenue multiple of around 3.0x. This suggests that Light Science, with its current revenue and operational loss, may be undervalued if it can successfully execute its growth strategy post-acquisition.
The execution track record of Light Science is mixed, with the company having set ambitious revenue targets in the past. The current acquisitions represent a pivotal moment for management to demonstrate its ability to meet these targets and effectively integrate the new businesses. However, a history of operational losses raises questions about management’s ability to execute on its growth plans without further dilution or capital raises. The acquisitions could provide a pathway to profitability, but they also introduce integration risks and the challenge of achieving the contingent revenue targets tied to the RLUK Injection acquisition.
One specific risk highlighted by this announcement is the reliance on shareholder approval for the fundraising, which could delay the acquisition process or result in a shortfall of necessary funds. Additionally, the company faces operational risks associated with integrating the new acquisitions and achieving the projected synergies. The next measurable catalyst will likely be the outcome of the shareholder vote scheduled for around April 9, 2026, which will determine the success of the fundraising efforts.
In conclusion, while the proposed acquisitions and fundraising initiative present a strategic opportunity for Light Science Technologies Holdings to enhance its market position and drive future growth, the reliance on external funding and shareholder approval introduces material risks. Given the current financial position and operational challenges, this announcement can be classified as significant, as it has the potential to materially impact the company's valuation and execution outlook, contingent upon successful fundraising and integration of the acquired entities.